Videos
Leukemia
Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.
Chronic Myeloid Leukemia
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ctDNA Assay Offers Prognostic Insights for Immunotherapy-Treated Solid Tumors
2
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer
5